Vertex Pharmaceuticals Inc / Ma: Form 10-K for the period ended Dec 31, 2019
Filed with the SEC on Feb 13, 2020 and accepted by EDGAR at Feb 13, 2020, 21:48 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-10-01 to 2019-12-31 | $1.41bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 12 months2019-01-01 to 2019-12-31 | $4.16bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2019-10-01 to 2019-12-31 | $185.0m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 12 months2019-01-01 to 2019-12-31 | $547.8m | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months2019-10-01 to 2019-12-31 | $480.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 12 months2019-01-01 to 2019-12-31 | $1.75bn | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2019-10-01 to 2019-12-31 | $195.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 12 months2019-01-01 to 2019-12-31 | $658.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2019-10-01 to 2019-12-31 | $551.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months2019-01-01 to 2019-12-31 | $1.20bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2019-10-01 to 2019-12-31 | $14.2m | us-gaap:InterestExpense |
| Interest expense | 12 months2019-01-01 to 2019-12-31 | $58.5m | us-gaap:InterestExpense |
| Income tax | 3 months2019-10-01 to 2019-12-31 | $93.7m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 12 months2019-01-01 to 2019-12-31 | $218.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-10-01 to 2019-12-31 | $583.2m | us-gaap:NetIncomeLoss |
| Net income | 12 months2019-01-01 to 2019-12-31 | $1.18bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-10-01 to 2019-12-31 | $2.23 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months2019-01-01 to 2019-12-31 | $4.51 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2019-10-01 to 2019-12-31 | $2.26 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months2019-01-01 to 2019-12-31 | $4.58 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2019-10-01 to 2019-12-31 | 262,108,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 12 months2019-01-01 to 2019-12-31 | 260,673,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2019-01-01 to 2019-12-31 | $1.57bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2019-01-01 to 2019-12-31 | $75.5m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months2019-01-01 to 2019-12-31 | $192.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2019-12-31 | $3.11bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-12-31 | $4.82bn | us-gaap:AssetsCurrent |
| Total assets | At period end2019-12-31 | $8.32bn | us-gaap:Assets |
| Current liabilities | At period end2019-12-31 | $1.33bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-12-31 | $2.23bn | us-gaap:Liabilities |
Source: SEC EDGAR, the filing index for accession 0000875320-20-000007. Last ingested by Listed: Nov 3, 2026, 18:50 ET. Listed shows no prices and gives no investment advice.